CURRICULUM VITAE

Preston C. Sprenkle, MD

Version Date: 2/15/2024

Contact Information:

Address	789 Howard Avenue Ste FMP315B New Haven, CT 06519
Phone:	1 (203) 785-7671
Email:	preston.sprenkle@yale.edu

School: Yale School of Medicine

Education:

xxxx - 01/1998	BA, Stanford University, Human Biology, Palo Alto, CA
xxxx - 01/2004	MD, Columbia University, New York, NY
09/2016 - 05/2018	Yale School of Management, Emerging Leaders Program, New Haven, CT

Career/Academic Appointments:

07/2004 - 06/2005	Internship, General Surgery, New York Presbyterian Hospital, New York, NY
07/2005 - 06/2009	Residency, Urology, New York Presbyterian Hospital, New York, NY
07/2009 - 12/2011	Fellowship, Urologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
09/2012 - 06/2018	Assistant Professor, Urology, Yale School of Medicine, New Haven, CT
07/2018 - 06/2024	Associate Professor on Term, Urology, Yale School of Medicine, New Haven, CT

Administrative Positions:

2014 - Present	Director, Urology Research Fellowship, Urology, Yale School of Medicine, New Haven, CT
2014 - 2023	Director, Urologic Oncology Clinical Fellowship Program, Urology, Yale School of Medicine, New Haven, CT
2015 - Present	Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology, VA Connecticut Healthcare System, West Haven, CT
2017 - Present	Co-Chair, Cancer Liaison Committee, Oncology, VA Connecticut Healthcare System, West Haven, CT
2019 - 2020	Chair, YNHH Robotics Committee, Yale New Haven Hospital, Yale New Haven Hospital, New Haven, CT

2021 - Present	Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA

Board Certification:

2014 - 2024	AB of Urology, Urology

Professional Honors & Recognition:

International/National/Regional

2004	Arnold P. Gold Humanism in Medicine Honors Society
2004	Alpha Omega Alpha Medical School Honors Society
2006	First Prize - NY section AUA Valentine Essay Contest, NY Academy of Medicine
2007	Finalist - NY section AUA Valentine Essay Contest, NY Academy of Medicine
2009	Best Poster Podium Presentation, Young Urologic Oncologist dinner, Society Of Urologic Oncology Annual Meeting
2009	Finalist - NY section AUA Valentine Essay Contest, NY Academy of Medicine

Yale University/Yale School of Medicine/Hospital System

1997	Member, Board of Directors, Stanford University Alumni Association
1998	Outstanding Member of Stanford Community, Stanford University
2017 - 2020	Mentor Appreciation Award, Interprofessional Longitudinal Clinical Experience
2021	2021 Thesis Reviewer, PA Master Thesis Committee, Yale School of Medicine

Grants/Clinical Trials History:

Current Grants

Agency:	Bio-Imaging's Inside MRI Grant
I.D.#:	GR113836
Title:	Inside-Out Nonlinear Gradients to Improve Diffusion MRI
P.I.:	Gigi Galiana
Role:	Investigator
Percent effort:	3%
Total costs:	$758,649.00
Project period:	07/06/2021 - 06/30/2026

Current Clinical Trials

Agency:	National Cancer Institute (NCI)
I.D.#:	0805003787
Title:	Genitourinary Cancer Data and Specimen Repository
P.I.:	Michael Hurwitz
Role:	Sub-Investigator
Percent effort:	N/A

Total costs:	0.0000
Project period:	10/03/2008 - ongoing

Agency:	Yale Cancer Center
I.D.#:	1304011902
Title:	MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	06/24/2013 - ongoing

Agency:	Yale Cancer Center
I.D.#:	1501015246
Title:	Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/13/2015 - ongoing

Agency:	Yale University School of Medicine
I.D.#:	1510016603REG
Title:	Focal Cryoablation of the Prostate: Tissue and Data Repository
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	12/16/2015 - ongoing

Agency:	Eastern Coop Onc Group-American College Radiology Imaging Netwk(ECOG-ACRIN)
I.D.#:	2000024244
Title:	Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
P.I.:	Jeffrey Weinreb
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	0.0000
Project period:	11/02/2018 - ongoing

Agency:	Southwest Oncology Group (SWOG)
I.D.#:	2000025125

Title:	Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	07/01/2019 - ongoing

Agency:	Profound Medical Inc.
I.D.#:	2000029224
Title:	Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
P.I.:	Sandeep Arora
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/03/2021 - ongoing

Agency:	Profound Medical Inc.
I.D.#:	2000030487
Title:	Customized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN)
P.I.:	Sandeep Arora
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	09/28/2021 - ongoing

Agency:	Yale Cancer Center
I.D.#:	2000031290
Title:	SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
P.I.:	Isaac Y. Kim
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	01/15/2022 - ongoing

Agency:	Rutgers, The State University of New Jersey
I.D.#:	2000031291
Title:	Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer
P.I.:	Isaac Y. Kim
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/27/2022 - ongoing

Agency:	Regeneron Pharmaceuticals, Inc.
I.D.#:	2000029991
Title:	A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
P.I.:	Joseph Kim
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	07/03/2022 - ongoing

Agency:	Amgen, Inc.
I.D.#:	2000027706
Title:	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
P.I.:	Daniel P. Petrylak
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	11/22/2022 - ongoing

Agency:	Curium US LLC
I.D.#:	2000031831
Title:	A Multi-Center, Open-Label, Randomized Phase 1/2 Study of Copper Cu 64 PSMA IT Injection in Patients with Histologically Proven Metastatic Prostate Cancer
P.I.:	Ming-Kai Chen
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	12/06/2022 - ongoing

Agency:	Southwest Oncology Group (SWOG)
I.D.#:	2000036263
Title:	Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
P.I.:	Joseph Kim
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	10/30/2023 - ongoing

Past Grants

Agency:	Department of Defense
I.D.#:	GR109111
Title:	Combining Therapeutic Response Genomic Signatures with Machine Learning to Predict Patient Outcome from Potentially Lethal Prostate Cancer
P.I.:	Darryl T. Martin
Role:	Investigator
Percent effort:	5%
Total costs:	$1,211,250.00
Project period:	07/01/2020 - 06/30/2023

Agency:	FDA/CERSI
I.D.#:	FR117786
Title:	Yale-Mayo Clinic FDA Center of Excellence in Regulatory Science and Innovation
P.I.:	Michael S. Leapman
Role:	Investigator
Percent effort:	2%
Total costs:	$8,631,957.34
Project period:	09/01/2022 - 08/31/2023

Agency:	Leet-Patterson Trust
I.D.#:	GR108958
Title:	2020 Seery Foundation Mentored Research Award for Cancer Research
P.I.:	Michael S. Leapman
Role:	Collaborator
Percent effort:	5%
Total costs:	$100,033.25
Project period:	04/30/2020 - 01/31/2023

Past Clinical Trials

Agency:	National Institutes of Health (NIH)
I.D.#:	1308012586

Title:	PDGFR-a, TERT Promoter Mutation and Polyamine Signaling in the Bladder Tissues
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	09/16/2013 - 09/10/2014

Agency:	Yale University School of Medicine
I.D.#:	1310012809
Title:	MR-US Fusion Prostate Biopsy Database
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	10/31/2013 - 10/14/2015

Agency:	Yale University School of Medicine
I.D.#:	1312013110
Title:	Active Surveillance of the Small Renal Mass
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/17/2014 - 02/11/2020

Agency:	Yale Cancer Center
I.D.#:	1402013376
Title:	Prostate Cancer Screening in Men with Germline BRCA2 Mutations
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	04/09/2014 - 07/15/2019

Agency:	Yale University School of Medicine
I.D.#:	1501015186EXEMPT
Title:	The impact of non-disease related factors on survival in patients with penile cancer
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	02/05/2015

Agency:	Progenics Pharmaceuticals
I.D.#:	1511016824
Title:	A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
P.I.:	Preston C. Sprenkle
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	0.0000
Project period:	03/16/2016 - 05/14/2018

Agency:	Progenics Pharmaceuticals
I.D.#:	1609018370
Title:	A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
P.I.:	Lawrence Saperstein
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	0.0000
Project period:	11/17/2016 - 08/30/2018

Agency:	BESO Biological Research, Inc.
I.D.#:	2000020868
Title:	Assessing the Clinical Response of Prostate Cancer to a Fermented Soy Extract
P.I.:	Michael S. Leapman
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/05/2017 - 04/27/2020

Agency:	Advanced Accelerator Applications International SA
I.D.#:	2000023359
Title:	A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
P.I.:	Lawrence Saperstein
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	10/11/2018 - 07/28/2020

Agency:	Progenics Pharmaceuticals
I.D.#:	2000024006

Title:	A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
P.I.:	Lawrence Saperstein
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	11/15/2018 - 01/28/2020

Pending Clinical Trials

Agency:	Yale University School of Medicine
I.D.#:	2000036492
Title:	Metabolic Effects of Exercise Among Patients with Prostate Cancer Prior to Radical Prostatectomy
P.I.:	Michael S. Leapman
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-

Agency:	Department of the Army
I.D.#:	2000027508
Title:	Determining Genomic Signatures of Prostate Cancer to Predict Subject Outcome
P.I.:	Darryl T. Martin
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/16/2020 - ongoing

Agency:	National Cancer Institute (NCI)
I.D.#:	2000030538
Title:	Inside-Out Nonlinear Gradients to Improve Diffusion MRI
P.I.:	Gigi Galiana
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	02/03/2022 - ongoing

Agency:	National Cancer Institute (NCI)
I.D.#:	2000035122
Title:	Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imaging
P.I.:	Michael S. Leapman
Role:	Sub-Investigator

Percent effort: N/A
Total costs: -
Project period: 04/20/2023 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale:

International/National

1. "Image Registration in MR-US Fusion biopsy". American Urological Association continuing education course, Image Registration in MR-US Fusion biopsy, Chicago, IL, January 2016. (Lecture)
2. "Focal ablation for prostate cancer". New England Section of AUA, Focal ablation for prostate cancer, Portland, ME, January 2016. (Oral Presentation)
3. "Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates". AdMeTech foundation Global Summit on Precision Diagnosis for Prostate Cancer, Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates, Boston, MA, January 2017. (Oral Presentation)
4. "Principles of Image Registration". American Urological Association continuing education course, Principles of Image Registration, Linthicum Heights, MD, January 2017. (Lecture)
5. "MR-US fusion biopsy in practice: Yale University experience". American Urological Association continuing education course, MR-US fusion biopsy in practice: Yale University experience, Linthicum Heights, MD, January 2017. (Oral Presentation)
6. "Yale experience with SpaceOAR rectal spacer". New England Section of AUA, Yale experience with SpaceOAR rectal spacer, Montreal, QC, Canada, January 2017. (Oral Presentation)
7. "Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates". AdMeTech foundation Global Summit on Precision Diagnosis for Prostate Cancer, Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates, Boston, MA, January 2018. (Oral Presentation)
8. "Hands On Training Course, MR-US fusion prostate biopsy tips and tricks". American Urological Association, Hands On Training Course, MR-US fusion prostate biopsy tips and tricks, San Francisco, CA, January 2018. (Demonstration)
9. "Hands-On demonstration of MR-US fusion prostate biopsy". American Urological Association, Hands-On demonstration of MR-US fusion prostate biopsy, Chicago, IL, January 2019. (Demonstration)
10. "Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates". AdMeTech foundation Global Summit on Precision Diagnosis for Prostate Cancer, Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates, Boston, MA, January 2019. (Oral Presentation)
11. "Integrating a rectal spacer procedure into urology practice". American Urological Association, Integrating a rectal spacer procedure into urology practice, Chicago, IL, January 2019. (Other)
12. "Prostate Cancer Session Moderator". New England Section of AUA, Prostate Cancer Session Moderator, Providence, RI, January 2019. (Other)
13. "Multimodal treatment of advanced prostate cancer, discussion panel member". New England Section of AUA, Multimodal treatment of advanced prostate cancer, discussion panel member, Providence, RI, January 2019. (Address)

14. "Diagnostic Test for Early Detection of Prostate Cancer, review of NCCN Guidelines update". AdMeTech Foundation, Diagnostic Test for Early Detection of Prostate Cancer, review of NCCN Guidelines update, Fourth Global Summit on Precision Diagnosis for Prostate Cancer, January 2020. (Oral Presentation)
15. "PSMA based imaging for management of prostate cancer". SNMMI Annual Meeting Satellite Symposium, PSMA based imaging for management of prostate cancer, Live virtual Round Table discussion with other Radiology and Urology experts in the field., January 2021. (Other)
16. "SpaceOAR VUE European Launch: Meet the Expert - Advancing Prostate Health". Boston Scientific Incorporated, SpaceOAR VUE European Launch: Meet the Expert - Advancing Prostate Health, Interviewed as Expert User of SpaceOAR VUE as part of the European launch of the product., January 2021. (Other)
17. "How to: Prostate Ultrasound". American Urological Association, How to: Prostate Ultrasound, Created instructional Video for AUA Educational Series, January 2021. (Demonstration)
18. "How To: Placement of Endorectal Spacer and Fiducial Markers". American Urological Association, How To: Placement of Endorectal Spacer and Fiducial Markers, Created instructional Video for AUA Educational Series, January 2021. (Demonstration)
19. "Negative prostate MRI, can prostate biopsy be avoided?". European Society of Medicine Congress 2021, Negative prostate MRI, can prostate biopsy be avoided?, Vienna, Vienna, Austria, January 2021. (Lecture)
20. "Update on NCCN Early Detection of Prostate Cancer Guidelines". AdMeTech Foundation, 5th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, Boston, MA, September 2021. (Oral Presentation)
21. "Negative Multiparametric MRI of the Prostate: can biopsy be avoided?". European Society of Medicine, European Society of Medicine Annual Congress, Vienna, Vienna, Austria, November 2021. (Lecture)
22. "Prostate cancer outcomes, comparing surgery and radiation. Side effects of robotic prostatectomy". AIS Channel, Prostate Caner Surgery versus Radiotherapy, the Current State of the Art, AIS Channel Live Surgery, March 2022. (Oral Presentation)
23. "New Treatments in Prostate Cancer, the TULSA Pro". Zero Cancer, Men Fighting Cancer Prostate Cancer support group, Participated in virtual support group for men with prostate cancer on the East Coast of the United States, April 2022. (Lecture)
24. "Molecular Diagnostics in the VA". VHA National Surgery Office, Prostate Cancer Diagnosis Symposium, Department of Veterans Affairs, National Surgery Office, February 2023. (Oral Presentation)
25. "Update on NCCN guidelines for Prostate Cancer Early Detection". AdMeTech Foundation, 7th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, International Summit Hosted by AdMeTech, September 2023. (Lecture)
26. "Margin Call: focal vs regional ablation for prostate cancer". FOCAL CME, FOCAL CME 2023, Chicago, IL, November 2023. (Lecture)

Regional

1. "Emerging role of MR-US fusion prostate biopsy". Connecticut Urological Association, Emerging role of MR-US fusion prostate biopsy, Hartford, CT, January 2015. (Oral Presentation)

2. "MR-US Fusion prostate biopsy: improving prostate cancer diagnosis". Association of Operating Room Nurses, MR-US Fusion prostate biopsy: improving prostate cancer diagnosis, West Haven, CT, January 2015. (Oral Presentation)
3. "Prostate Cancer Screening". SCAN-ECHO regional educational conference, Prostate Cancer Screening, West Haven, CT, January 2015. (Oral Presentation)
4. "Session Moderator: Prostate cancer genomics panel". New England Section of AUA, Session Moderator: Prostate cancer genomics panel, Hartford, CT, January 2018. (Address)
5. "Prostate Biopsy: Transrectal vs Transperineal approach". New England Section of the American Urological Association, New England Section of American Urological Association Annual Meeting, Portland, ME, September 2022. (Oral Presentation)

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. The bladder trigone is not a Wolffian duct remnant. American Urological Association, The bladder trigone is not a Wolffian duct remnant, San Francisco, CA, January 2006. (Oral Presentation)
2. B7x is a serum marker for prostate cancer. Society of Urological Oncology Annual meeting, B7x is a serum marker for prostate cancer, Bethesda, MD, January 2009. (Oral Presentation)
3. Urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a marker for Acute Kidney Injury in Kidney Surgery Patients. Society of Urologic Oncology, Urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a marker for Acute Kidney Injury in Kidney Surgery Patients, Bethesda, MD, January 2012. (Oral Presentation)
4. MRI-US fusion prostate biopsy, improving cancer detection. New England Section AUA, MRI-US fusion prostate biopsy, improving cancer detection, Providence, RI, January 2014. (Oral Presentation)
5. MRI targeted biopsy alone is inadequate to detect clinically significant prostate cancer: a meta-analysis.. New England Section of AUA, MRI targeted biopsy alone is inadequate to detect clinically significant prostate cancer: a meta-analysis., Nassau, New Providence, Bahamas, January 2015. (Oral Presentation)
6. MRI-Fusion biopsy in a first-time biopsy cohort yields increased detection of clinically significant cancer using a simplified MRI grading scale.. American Urological Association, MRI-Fusion biopsy in a firt-time biopsy cohort yields increased detection of clinically significant cancer using a simplified MRI grading scale., Orlando, FL, January 2015. (Oral Presentation)
7. Should we still biopsy patients with a negative MP-MRI?. American Urological Association Annual Meeting, Should we still biopsy patients with a negative MP-MRI?, San Diego, CA, January 2016. (Oral Presentation)
8. MR-US Fusion Biopsy, West Haven VA experience. American Urological Association, MR-US Fusion Biopsy, West Haven VA experience, Boston, MA, January 2017. (Oral Presentation)
9. Outcomes of Serial MRI-Fusion Biopsy in Men with Prostate Cancer Managed with Active Surveillance. AdMeTech foundation Global Summit on Precision Diagnosis for Prostate Cancer, Outcomes of Serial MRI-Fusion Biopsy in Men with Prostate Cancer Managed with Active Surveillance, Boston, MA, January 2017. (Oral Presentation)

10. Physician learning curve using MR-US fusion prostate biopsy. New England Section of AUA, Physician learning curve using MR-US fusion prostate biopsy, Montreal, QC, Canada, January 2017. (Oral Presentation)

Professional Service:

Peer Review Groups/Grant Study Sections

2014 - 2021	Board Member, NCCN Prostate Cancer Early Detection Guideline Panel
2019	Ad-hoc reviewer, NIH, Ad Hoc reviewer for NIH Clinical Trials Genitourinary Steering Committee
2021 - Present	Grant Reviewer, Prostate Cancer UK, Review Prostate Cancer UK grants for consideration for funding. typically 2-3 grants/year
2021 - Present	Member, VHA National Surgery Office - Robotic Surgery Surgical Advisory Board
2021 - Present	Vice Chair, NCCN Prostate Cancer Early Detection Guideline Panel
2023	Thesis Reviewer, PhD candidate Thesis examiner - Joanna Chen

Advisory Boards

2019 - Present	Advisor, Scientific Advisory Board, Boston Scientific Inc., Scientific review and advice on urologic products
2022 - Present	Board Member, Clinical Advisory Board, Profound Medical

Journal Services

Editorial boards

2015 - Present	Associate Editor, Frontiers

Reviewer

2009 - Present	Reviewer, Journal of Urology
2009 - Present	Reviewer, Frontiers in Science
2009 - Present	Reviewer, Urology
2015 - Present	Reviewer, Clinical Genitourinary Cancer
2015 - Present	Reviewer, PLOS One
2016 - Present	Reviewer, Urologic Oncology
2016 - Present	Reviewer, Oncotarget
2016 - Present	Reviewer, Nature Scientific Reports
2021 - Present	Reviewer, European Urology

Professional Organizations

American Association of Clinical Urologists

2006 - Present	Member, American Association of Clinical Urologists

Society of Urologic Oncology

2009 - Present Member, Society of Urologic Oncology

Yale Interdisciplinary Prostate Program

2015 - Present Founding Member, Yale Interdisciplinary Prostate Program, Interdisciplinary group focused on collaborative research and development of clinical programs in prostate cancer

Yale University / Hospital System

Medical School

2021 - 2023 Member, Department of Urology Medical Student Thesis review committee

Department

2015 - 2019 Member, Department of Urology Residency Promotion Committee

2016 - Present Member, Department of Urology Executive Committee

Hospital

2014 - 2016 Member, Urologic Clinical Cost and Value Committee

2014 - 2016 Expert Panel Member, Interventional Radiology Purchasing Committee

2018 - Present Representative, MCIC LLC, Surgeon representative on multi-institutional meetings to improve clinical outcomes

2020 - 2021 Chair, Robotic Credentialing and Privileging committee, Multidisciplinary committee to review and define acceptable requirements to attain and maintain robotic surgery privileges.

Public Service / Media Presence

Public Service

2008 Participant, Washington Heights free prostate cancer education and screening clinic

2015 - Present Participant, Yale Urology Prostate Cancer Screening Clinic

Bibliography:

Peer-Reviewed Original Research

1. **Sprenkle P**, Batourina E, Tsai S, Lambert S, Paragas N, Glassberg K, Hensle T, Mendelsohn C. 1717: The Bladder Trigone is not a Wolffian Duct Remnant. Investigative Urology 2004, 171: 454. DOI: 10.1016/s0022-5347(18)38909-2.
2. Batourina E, Tsai S, Lambert S, **Sprenkle P**, Viana R, Dutta S, Hensle T, Wang F, Niederreither K, McMahon AP, Carroll TJ, Mendelsohn CL. Apoptosis induced by vitamin A signaling is crucial for connecting the ureters to the bladder. Nature Genetics 2005, 37: 1082-1089. PMID: 16186816, DOI: 10.1038/ng1645.

3. Lambert S, Batourina E, Tsai S, Viana R, **Sprenkle P**, Dutta S, Hensle T, Mendelsohn C. 578: Distal Ureteral Morphogenesis Depends on Apoptosis Induced by Signals from the Urogenital Sinus: A New Model of Ureteral Maturation. Investigative Urology 2006, 175: 187-188. DOI: 10.1016/s0022-5347(18)32824-6.
4. **Sprenkle P**, Lowe F. Benign prostate hyperplasia in the older male. Aging Health 2007, 3: 177-189. DOI: 10.2217/1745509x.3.2.177.
5. Pierorazio PM, Lambert SM, Matsukhani M, **Sprenkle PC**, McCann TR, Katz AE, Olsson CA, Benson MC, McKiernan JM. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. BJU International 2007, 100: 1066-1070. PMID: 17784880, DOI: 10.1111/j.1464-410x.2007.07115.x.
6. Pierorazio P, Lambert S, Matsukhani M, **Sprenkle P**, McCann T, Katz A, Olsson C, Benson M, McKiernan J. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. BJU International 2007, 0: 070907021207002-???. DOI: 10.1111/j.1464-410x.2007.07115.x.
7. **Sprenkle PC**, Fisch H. Pathologic effects of testosterone deprivation. Current Opinion In Urology 2007, 17: 424-430. PMID: 17921778, DOI: 10.1097/mou.0b013e3282f0ebef.
8. Hruby GW, **Sprenkle PC**, Abdelshehid C, Clayman RV, McDougall EM, Landman J. The EZ Trainer: Validation of a Portable and Inexpensive Simulator for Training Basic Laparoscopic Skills. Investigative Urology 2007, 179: 662-666. PMID: 18082210, DOI: 10.1016/j.juro.2007.09.030.
9. Hruby G, **Sprenkle P**, Lehman D, Durak E, Marruffo F, Mirabile G, McKiernan J, Gupta M, Landman J. COMPARISON OF COMPLETE INTRACORPOREAL CONSTRUCTION OF AN ILEUM NEOBLADDER UTILIZING STANDARD SUTURED TECHNIQUES AND NOVEL TECHNOLOGIES. Investigative Urology 2008, 179: 248. DOI: 10.1016/s0022-5347(08)60716-8.
10. **Sprenkle P**, Mirabile G, Hruby G, Phillips C, Xavier K, Gupta M, Landman J. THE EFFECT OF ARGON GAS PRESSURE ON ICE BALL SIZE AND RATE OF FORMATION. Investigative Urology 2008, 179: 243-244. DOI: 10.1016/s0022-5347(08)60703-x.
11. Durak E, Hruby GW, Okhunov Z, **Sprenkle P**, Mirabile G, Marruffo F, Landman J. Complete Ileal Neobladder Intracorporeal Construction With Standard Sutured Technique and Novel Technology. Investigative Urology 2010, 183: 1227-1231. PMID: 20096862, DOI: 10.1016/j.juro.2009.11.005.
12. **Sprenkle PC**, Mirabile G, Durak E, Edelstein A, Gupta M, Hruby GW, Okhunov Z, Landman J. The Effect of Argon Gas Pressure on Ice Ball Size and Rate of Formation. Journal Of Endourology 2010, 24: 1503-1507. PMID: 20649444, DOI: 10.1089/end.2009.0587.
13. Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, **Sprenkle P**, Gupta A, Taylor J, Bernstein M, Adeniran A, Tickoo SK, Reuter VE, Russo P. Prognostic Impact of Muscular Venous Branch Invasion in Localized Renal Cell Carcinoma Cases. Investigative Urology 2010, 185: 37-42. PMID: 21074196, PMCID: PMC3437930, DOI: 10.1016/j.juro.2010.08.084.
14. **Sprenkle P**, Sankin A, Savage C, Musser J, Touijer K, Russo P, Coleman J. 1269 OUTCOMES FOLLOWING RENAL SURGERY IN HIGH-RISK PATIENTS: A NON-RANDOMIZED COMPARISON OF OPEN AND MINIMALLY INVASIVE SURGICAL APPROACHES. Investigative Urology 2011, 185: e507. DOI: 10.1016/j.juro.2011.02.954.
15. **Sprenkle P**, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, Goluboff E, Benson M, Rutman M. Exploring medical student education initiatives: does the management of urologic conditions improve with a formal urology clinical clerkship? Journal Of Medicine And The Person 2011, 9: 116-122. DOI: 10.1007/s12682-011-0101-y.

16. **Sprenkle P**, Russo P. Molecular markers for ischemia, do we have something better then creatinine and glomerular filtration rate? Archivos Españoles De Urología 2013, 66: 99-114. PMID: 23406805.
17. **Sprenkle PC**, Wren J, Maschino AC, Feifer A, Power N, Ghoneim T, Sternberg I, Fleisher M, Russo P. Urine Neutrophil Gelatinase-Associated Lipocalin as a Marker of Acute Kidney Injury After Kidney Surgery. Investigative Urology 2013, 190: 159-164. PMID: 23391468, PMCID: PMC4167359, DOI: 10.1016/j.juro.2013.01.101.
18. Silberstein JL, **Sprenkle PC**, Su D, Power NE, Tarin TV, Ezell P, Sjoberg DD, Feifer A, Fleisher M, Russo P, Touijer KA. NGAL response to ischaemia in two-kidney porcine model. BJU International 2013, 112: 517-525. PMID: 23510358, PMCID: PMC4235973, DOI: 10.1111/bju.12066.
19. Cornfeld D, **Sprenkle P**. Multiparametric MRi: standardizations needed. Oncology 2013, 27: 277,280. PMID: 23781691.
20. Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, **Sprenkle P**. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.
21. Kardos S, Pan S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, **Sprenkle P**. MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE. Investigative Urology 2015, 193: e179. DOI: 10.1016/j.juro.2015.02.850.
22. Karnes R, Loeb S, **Sprenkle P**, Morrell C, MacKintosh F, Rawson L, Neville T. MP86-08 CONFIRMATION: ANALYSIS OF PSA TRENDS HELPS IDENTIFY DEADLY PROSTATE CANCERS PRIOR TO BIOPSY. Investigative Urology 2015, 193: e1078-e1079. DOI: 10.1016/j.juro.2015.02.1917.
23. Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, **Sprenkle P**, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT. Gleason 6 Prostate Cancer: Translating Biology into Population Health. Investigative Urology 2015, 194: 626-634. PMID: 25849602, PMCID: PMC4551510, DOI: 10.1016/j.juro.2015.01.126.
24. Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, **Sprenkle P**. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.
25. Nawaf C, Rosoff J, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, **Sprenkle P**. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.
26. Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, **Sprenkle P**. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.
27. Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Humphrey P, Levi A, **Sprenkle P**. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.
28. Ehrenberg H, Cornfeld D, Nawaf C, **Sprenkle P**, Duncan J. Decision forests for learning prostate cancer probability maps from multiparametric MRI. Proceedings Of SPIE 2016, 9785: 97851j-97851j-14. DOI: 10.1117/12.2216904.

29. Lu A, Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, **Sprenkle P**. PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS? Investigative Urology 2016, 195: e393. DOI: 10.1016/j.juro.2016.02.1137.
30. Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, **Sprenkle P**. MP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCER. Investigative Urology 2016, 195: e158. DOI: 10.1016/j.juro.2016.02.2541.
31. Nguyen K, Nawaf C, Levi A, Huber S, Lu A, Say R, **Sprenkle P**. Bacillus Calmette–Guérin therapy-induced granulomatous prostatitis on multiparametric magnetic resonance imaging: a case report. Journal Of Clinical Urology 2016, 10: 280-282. DOI: 10.1177/2051415816651561.
32. MacKintosh FR, **Sprenkle PC**, Walter LC, Rawson L, Karnes RJ, Morrell CH, Kattan MW, Nawaf CB, Neville TB. Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. Frontiers In Oncology 2016, 6: 157. PMID: 27446803, PMCID: PMC4923265, DOI: 10.3389/fonc.2016.00157.
33. Syed JS, Javier-Desloges J, Tatzel S, Bhagat A, Nguyen KA, Hwang K, Kim S, **Sprenkle PC**. Current Management Strategy for Active Surveillance in Prostate Cancer. Current Oncology Reports 2017, 19: 11. PMID: 28220449, DOI: 10.1007/s11912-017-0569-6.
34. Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, **Sprenkle P**. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.
35. Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, **Sprenkle PC**. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. PMID: 28322902, DOI: 10.1016/j.urology.2017.01.048.
36. Onofrey JA, Staib LH, Sarkar S, Venkataraman R, Nawaf CB, **Sprenkle PC**, Papademetris X. Learning Non-rigid Deformations for Robust, Constrained Point-based Registration in Image-Guided MR-TRUS Prostate Intervention. Medical Image Analysis 2017, 39: 29-43. PMID: 28431275, PMCID: PMC5514316, DOI: 10.1016/j.media.2017.04.001.
37. Syed JS, Lu A, Nguyen KA, **Sprenkle PC**, Weinreb JC. Author Reply. Urology 2017, 105: 122. PMID: 28449978, DOI: 10.1016/j.urology.2017.01.050.
38. Syed JS, Nguyen KA, Nawaf CB, Bhagat AM, Huber S, Levi A, Humphrey P, Weinreb JC, Schulam PG, **Sprenkle PC**. Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion–targeted biopsy in patients with a solitary PI-RADS v2–scored lesion. Urologic Oncology Seminars And Original Investigations 2017, 35: 542.e19-542.e24. PMID: 28501565, DOI: 10.1016/j.urolonc.2017.04.011.
39. Sheridan AD, Nath SK, Syed JS, Aneja S, **Sprenkle PC**, Weinreb JC, Spektor M. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI. American Journal Of Roentgenology 2017, 210: 347-357. PMID: 29112469, DOI: 10.2214/ajr.17.18516.
40. Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, **Sprenkle P**. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.

41. Lu A, Ghabili K, Nguyen K, Leapman M, **Sprenkle P**. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.
42. Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, **Sprenkle P**. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.
43. Lu A, Ghabili K, Nguyen K, **Sprenkle P**. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.
44. Sheridan AD, Nath SK, Aneja S, Syed JS, Pahade J, Mathur M, **Sprenkle P**, Weinreb JC, Spektor M. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI. American Journal Of Roentgenology 2018, 210: w218-w225. PMID: 29489409, DOI: 10.2214/ajr.17.18680.
45. Amirkhiz K, Suarez-Sarmiento A, Nguyen K, Hsiang W, Amalraj S, Syed J, Leapman M, Schulam P, **Sprenkle P**. MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY. Investigative Urology 2018, 199: e707-e708. DOI: 10.1016/j.juro.2018.02.1681.
46. Lu A, Amirkhiz K, Nguyen K, Leapman M, **Sprenkle P**. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Investigative Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.
47. Hsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, **Sprenkle P**. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE. Investigative Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.
48. Wang N, Fan R, **Sprenkle P**, Sonn G. MP77-19 CLINICAL TOOL PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN. Investigative Urology 2018, 199: e1035. DOI: 10.1016/j.juro.2018.02.2607.
49. Leung C, Syed J, Pan S, Neville T, **Sprenkle P**. MP01-20 THE LEARNING CURVE FOR MULTI-PARAMETRIC MRI/US FUSION GUIDED PROSTATE BIOPSY: A SINGLE CENTER EXPERIENCE. Investigative Urology 2018, 199: e11. DOI: 10.1016/j.juro.2018.02.126.
50. Karnes RJ, MacKintosh FR, Morrell CH, Rawson L, **Sprenkle PC**, Kattan MW, Colicchia M, Neville TB. Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort. Frontiers In Oncology 2018, 8: 296. PMID: 30128303, PMCID: PMC6088151, DOI: 10.3389/fonc.2018.00296.
51. Martin DT, Ghabili K, Levi A, Humphrey PA, **Sprenkle PC**. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology 2018, 125: 64-72. PMID: 30552940, DOI: 10.1016/j.urology.2018.12.001.
52. Onofrey JA, Casetti-Dinescu DI, Lauritzen AD, Sarkar S, Venkataraman R, Fan RE, Sonn GA, **Sprenkle PC**, Staib LH, Papademetris X. Generalizable Multi-Site Training and Testing Of Deep Neural Networks Using Image Normalization. 2011 IEEE International Symposium On Biomedical Imaging:

From Nano To Macro 2019, 00: 348-351. PMID: 32874427, PMCID: PMC7457546, DOI: 10.1109/isbi.2019.8759295.

53. Yang D, Yu J, An Y, **Sprenkle P**, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.
54. Martin D, Ghabili* K, Levi A, Humphrey P, Schulam P, **Sprenkle P**. PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2. Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000555367.28091.c8.
55. Abello* A, **Sprenkle P**, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
56. Javier-DesLoges* J, Abello A, Syed J, **Sprenkle P**, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
57. Lu AJ, Syed JS, Ghabili K, Hsiang WR, Nguyen KA, Leapman MS, **Sprenkle PC**. Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy. European Urology 2019, 76: 14-17. PMID: 31047733, DOI: 10.1016/j.eururo.2019.04.008.
58. Hsiang W, Ghabili K, Syed JS, Holder J, Nguyen KA, Suarez-Sarmiento A, Huber S, Leapman MS, **Sprenkle PC**. Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance. European Urology Focus 2019, 7: 47-54. PMID: 31147263, DOI: 10.1016/j.euf.2019.05.011.
59. Ghabili K, Swallow M, Sherrer RL, Syed JS, Khajir G, Gordetsky JB, Leapman MS, Rais-Bahrami S, **Sprenkle PC**. Association Between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4. Urology 2019, 134: 173-180. PMID: 31419433, DOI: 10.1016/j.urology.2019.08.008.
60. Syed J, **Sprenkle P**. Benign and Malignant Diseases of the Prostate. 2019, 1-32. DOI: 10.1007/978-3-319-20317-1_79-1.
61. Grinberg AS, Sellinger J, **Sprenkle PC**, Bandin AJ, Nawaf CB, Syed JS, Leapman MS. Effect of Diaphragmatic Breathing on Procedural Anxiety During Transrectal Prostate Biopsy. Urology 2019, 137: 26-32. PMID: 31893532, DOI: 10.1016/j.urology.2019.12.024.
62. Rajwa P, **Sprenkle PC**, Leapman MS. When and How Should Active Surveillance for Prostate Cancer be De-Escalated? European Urology Focus 2020, 7: 297-300. PMID: 32019719, PMCID: PMC7394715, DOI: 10.1016/j.euf.2020.01.001.
63. Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, **Sprenkle P**, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.
64. Abello* A, Nawaf C, Brito J, **Sprenkle P**, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL

CYSTECTOMY. Investigative Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.

65. **Sprenkle* P**, Carroll P, Probst S, Gorin M, Rowe S, Pienta K, Pouliot F, Patnaik A, Preston M, Alva A, Siegel B, Morris M. PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL. Investigative Urology 2020, 203 DOI: 10.1097/ju.0000000000000917.05.
66. Ghabili K, Park HS, Yu JB, **Sprenkle PC**, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal Of Urology 2020, 39: 1141-1151. PMID: 32562045, DOI: 10.1007/s00345-020-03298-6.
67. Abello A, Brito J, **Sprenkle P**, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy. European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
68. Syed J, **Sprenkle P**. Benign and Malignant Diseases of the Prostate. 2020, 651-682. DOI: 10.1007/978-3-319-47771-8_79.
69. Yang DX, Verma V, An Y, Yu JB, **Sprenkle PC**, Leapman MS, Park HS. Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Advances In Radiation Oncology 2020, 5: 1225-1231. PMID: 33305083, PMCID: PMC7718530, DOI: 10.1016/j.adro.2020.08.015.
70. Torres R, Olson E, Homer R, Martin DT, Levene MJ, Perincheri S, **Sprenkle PC**, Humphrey PA. Initial Evaluation of Rapid, Direct-to-Digital Prostate Biopsy Pathology. Archives Of Pathology Laboratory Medicine 2020, 145: 583-591. PMID: 32991670, DOI: 10.5858/arpa.2020-0037-oa.
71. Ghabili K, Paulson N, Syed JS, Nawaf CB, Khajir G, Martin DT, Onofrey J, Leapman MS, Levi A, Weinreb JC, Humphrey PA, **Sprenkle PC**. Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. Case Reports In Urology 2021, 2021: 2687416. PMID: 33936831, PMCID: PMC8054861, DOI: 10.1155/2021/2687416.
72. Rajwa P, Mori K, Huebner NA, Martin DT, **Sprenkle PC**, Weinreb JC, Ploussard G, Pradere B, Shariat SF, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Investigative Urology 2021, 206: 507-516. PMID: 33904755, DOI: 10.1097/ju.0000000000001821.
73. Paulson N, Vollmer RT, Humphrey PA, **Sprenkle PC**, Onofrey J, Huber S, Amirkhiz K, Levi AW. Extent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage. Archives Of Pathology Laboratory Medicine 2021, 146: 201-204. PMID: 34015819, DOI: 10.5858/arpa.2020-0568-oa.
74. Wibmer AG, Kattan MW, Alessandrino F, Baur ADJ, Boesen L, Franco FB, Bonekamp D, Campa R, Cash H, Catalá V, Crouzet S, Dinnoo S, Eastham J, Fennessy FM, Ghabili K, Hohenfellner M, Levi AW, Ji X, Løgager V, Margolis DJ, Moldovan PC, Panebianco V, Penzkofer T, Puech P, Radtke JP, Rouvière O, Schlemmer HP, **Sprenkle PC**, Tempany CM, Vilanova JC, Weinreb J, Hricak H, Shukla-Dave A. International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer. Cancers 2021, 13: 2627. PMID: 34071842, PMCID: PMC8198352, DOI: 10.3390/cancers13112627.

75. Press BH, Khajir G, Ghabili K, Leung C, Fan RE, Wang NN, Leapman MS, Sonn GA, **Sprenkle PC**. Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI. Urology 2021, 155: 96-100. PMID: 34087311, DOI: 10.1016/j.urology.2021.05.035.
76. Wang NN, Zhou SR, Chen L, Tibshirani R, Fan RE, Ghanouni P, Thong AE, To'o KJ, Ghabili K, Nix JW, Gordetsky JB, **Sprenkle P**, Rais-Bahrami S, Sonn GA. The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer. Urologic Oncology Seminars And Original Investigations 2021, 39: 831.e19-831.e27. PMID: 34247909, DOI: 10.1016/j.urolonc.2021.06.004.
77. Fang A, Shumaker L, Khajir G, Fan R, Soodana-Prakash N, Patel H, **Sprenkle P**, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Investigative Urology 2021, 206: e78-e78. DOI: 10.1097/ju.0000000000001972.05.
78. Press B, Khajir G, Olawoyin O, Leapman M, **Sprenkle P**. MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSY. Investigative Urology 2021, 206: e468-e468. DOI: 10.1097/ju.0000000000002023.14.
79. Leapman MS, Wang R, Park HS, Yu JB, **Sprenkle PC**, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.
80. Martin DT, Lee JS, Liu Q, Galiana G, **Sprenkle PC**, Humphrey PA, Petrylak DP, Weinreb JC, Schulam PG, Weiss RM, Fahmy TM. Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. Nanomedicine Nanotechnology Biology And Medicine 2021, 40: 102477. PMID: 34740868, DOI: 10.1016/j.nano.2021.102477.
81. Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, **Sprenkle P**, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
82. Leapman MS, Wang R, Park H, Yu JB, **Sprenkle PC**, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.
83. Lokeshwar SD, Syed JS, Segal D, Rahman SN, **Sprenkle PC**. Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer. Current Oncology Reports 2022, 24: 249-256. PMID: 35080739, DOI: 10.1007/s11912-021-01180-1.
84. Press BH, Jones T, Olawoyin O, Lokeshwar SD, Rahman SN, Khajir G, Lin DW, Cooperberg MR, Loeb S, Darst BF, Zheng Y, Chen RC, Witte JS, Seibert TM, Catalona WJ, Leapman MS, **Sprenkle PC**. Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. European Urology Open Science 2022, 37: 113-119. PMID: 35243396, PMCID: PMC8883188, DOI: 10.1016/j.euros.2022.01.008.
85. Khajir G, Press B, Levi A, **Sprenkle P**, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.

86. Masoom SN, Sundaram KM, Ghanouni P, Fütterer J, Oto A, Ayyagari R, **Sprenkle P**, Weinreb J, Arora S. Real-Time MRI-Guided Prostate Interventions. Cancers 2022, 14: 1860. PMID: 35454773, PMCID: PMC9030365, DOI: 10.3390/cancers14081860.
87. Khajir G, Press B, **Sprenkle P**, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES. Investigative Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.
88. Khajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, **Sprenkle P**. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Investigative Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.
89. Fang A, Shumaker L, Martin K, Onah O, Jackson J, Khajir G, Fan R, Soodana-Prakash N, Patel H, Vourganti S, Filson C, **Sprenkle P**, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Investigative Urology 2022, 207: e959. DOI: 10.1097/ju.0000000000002637.01.
90. Leapman M, Long J, Wang R, **Sprenkle P**, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING. Investigative Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
91. Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, **Sprenkle PC**. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.
92. Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana-Prakash N, Vourganti S, Filson CP, Sonn GA, **Sprenkle PC**, Gupta GN, Punnen S, Rais-Bahrami S. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.
93. Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, **Sprenkle PC**, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.
94. Novosel M, Smani S, Marks V, Jeong F, **Sprenkle P**, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Journal Of Clinical Oncology 2023, 41: 307-307. DOI: 10.1200/jco.2023.41.6_suppl.307.
95. Smani S, Novosel M, Jeong F, Marks V, **Sprenkle P**, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.
96. Lee J, Ghanouni P, Costa D, Shin C, Khalighinejad P, **Sprenkle P**, Staruch R, Beserra A, Arora S. Abstract No. 160 MR Susceptibility-Weighted Imaging During Transurethral Prostate Sono-Ablation Procedures for Guidance of Device Placement to Counter Effect of Intra-Prostatic Calcifications. Journal Of Vascular And Interventional Radiology 2023, 34: s74-s75. DOI: 10.1016/j.jvir.2022.12.214.

97. Moses K, **Sprenkle P**, Bahler C, Box G, Carlsson S, Catalona W, Dahl D, Dall'Era M, Davis J, Drake B, Epstein J, Etzioni R, Farrington T, Garraway I, Jarrard D, Kauffman E, Kaye D, Kibel A, LaGrange C, Maroni P, Ponsky L, Reys B, Salami S, Sanchez A, Seibert T, Shaneyfelt T, Smaldone M, Sonn G, Tyson M, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi R, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 236-246. PMID: 36898362, DOI: 10.6004/jnccn.2023.0014.
98. Esmaili R, Khajir G, Leapman M, **Sprenkle P**, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Investigative Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.
99. Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, **Sprenkle P**, Ross A. MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET. Investigative Urology 2023, 209: e212. DOI: 10.1097/ju.0000000000003237.02.
100. Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Ross A, **Sprenkle P**. MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE. Investigative Urology 2023, 209: e216. DOI: 10.1097/ju.0000000000003237.09.
101. Leapman M, Wang R, Long J, **Sprenkle P**, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Investigative Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.
102. Novosel M, Smani S, Marks V, Jeong F, **Sprenkle P**, Leapman M. PD20-07 ASSOCIATIONS BETWEEN PATIENT SOCIODEMOGRAPHIC FACTORS AND RISK-APPROPRIATE PROSTATE CANCER MANAGEMENT. Investigative Urology 2023, 209: e586. DOI: 10.1097/ju.0000000000003286.07.
103. Smani S, Novosel M, Marks V, Jeong F, **Sprenkle P**, Leapman M. MP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFE. Investigative Urology 2023, 209: e1079. DOI: 10.1097/ju.0000000000003349.01.
104. Khan A, Choksi A, Rahman S, Press B, Jalfon M, Gardezi M, Jones T, Hayden C, Ghiraldi E, Siev M, Lacy G, **Sprenkle P**, Kellner D. MP59-12 CAN ANATOMICAL MEASUREMENTS ON PREOPERATIVE PELVIC MAGNETIC RESONANCE IMAGING PREDICT POSTOPERATIVE URINARY INCONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE? Investigative Urology 2023, 209: e812. DOI: 10.1097/ju.0000000000003312.12.
105. Zeevi T, Leapman M, **Sprenkle P**, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping from MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2023, PP: 1-8. PMID: 37874731, DOI: 10.1109/tbme.2023.3326799.
106. Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, **Sprenkle P**, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.
107. Khajir G, Sun T, Wang H, **Sprenkle P**, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting

Urine Cytology second edition with histopathologic follow-up. Cytopathology 2023 PMID: 37916579, DOI: 10.1111/cyt.13328.

108. Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, **Sprenkle P**, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023 PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.